ENTITY

Symbio Pharmaceuticals (4582 JP)

43
Analysis
Health Care • Japan
Symbio Pharmaceuticals Limited develops and commercializes prescription drugs n oncology, hematology and auto-immune disease for Japan and other Asia Pacific markets.
more
•26 May 2020 14:52•Issuer-paid

SymBio Pharmaceuticals - Top-line data from registrational DLBCL study

SymBio will be presenting data at the European Society of Hematology (EHA) meeting from its pivotal study in Japan of Treakisym (bendamustine) in...

Share
•22 May 2020 19:11•Issuer-paid

SymBio Pharmaceuticals - Treakisym label expansion submitted

SymBio announced on 11 May 2020 that it submitted an application to expand the label for Treakisym in Japan to include the treatment of relapsed...

Share
•19 May 2020 14:36•Issuer-paid

SymBio Pharmaceuticals - Treakisym label expansion submitted

SymBio announced on 11 May 2020 that it submitted an application to expand the label for Treakisym in Japan to include the treatment of relapsed...

Share
•21 Feb 2020 22:30•Issuer-paid

SymBio Pharmaceuticals - Supply issues continue

SymBio reported sales of $25.8m (¥2.838bn) for 2019 and an operating loss of $39.1 (¥4.301bn). Sales were down from 2018 due to the previously...

Share
•21 Feb 2020 16:46•Issuer-paid

SymBio Pharmaceuticals - Supply issues continue

SymBio reported sales of ¥2.838bn for 2019 and an operating loss of ¥4.301bn. Sales were down from 2018 due to the previously announced quality...

Share
x